Literature DB >> 6605993

Inhibition of interleukin 2 production by factors released from tumor cells.

P Hersey, C Bindon, M Czerniecki, A Spurling, J Wass, W H McCarthy.   

Abstract

In previous studies, cultured melanoma cells were shown to have a suppressive influence on the induction of cytotoxic T cells. Our investigation of the mechanism of these effects revealed that supernatants from certain cultures of melanoma cells contained inhibitory activity against the production of interleukin 2 (IL 2) from phytohemagglutinin (PHA)-stimulated cultures of lymphocytes. These supernatants did not inhibit interleukin 1 production, and also did not inhibit the mitogenic activity of performed IL 2 on IL 2-dependent target cells. Production of the inhibitory activity could be reduced by inhibitors of protein synthesis, but this activity was not inhibited by digestion with the proteolytic enzymes trypsin or pronase. Gel filtration analysis of tumor supernatants revealed that the majority of the inhibitory activity was detected in fractions of approximately 44 and 7 Kd. The addition of supernatants with inhibitory activity to PHA-stimulated cultures of lymphocytes was associated with reduced transition of cells from G1 to S phase of cell division, which could be reversed by the addition of IL 2. Preliminary studies suggest that the release of the factor(s) from melanoma cells may be related to rapid progression of tumor growth in patients, and therefore may be of prognostic significance in tumor host relationships.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605993

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 2.  Need for immunologic stimulators during immunosuppression produced by major cancer surgery.

Authors:  W H Cole; L Humphrey
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

3.  Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.

Authors:  D Taramelli; A Mazzocchi; C Clemente; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 4.  Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions.

Authors:  A L de Weck; F Kristensen; F Joncourt; F Bettens; C Walker; Y Wang
Journal:  Springer Semin Immunopathol       Date:  1984

5.  High endothelial venule and immunocompetent cells in typical medullary carcinoma of the breast.

Authors:  H Tanaka; M Hori; T Ohki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

6.  Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes.

Authors:  J P Siegel; J Y Djeu; N I Stocks; H Masur; E P Gelmann; G V Quinnan
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

7.  Decreased interleukin generation in patients with cancer of the digestive system. A correlation between interleukin 1 and interleukin 2 production.

Authors:  Y Haga; K Sakamoto; Y Yokoyama; M Akagi
Journal:  Jpn J Surg       Date:  1988-09

8.  Effect of tumor-derived immunosuppressive factor(s) on interleukin 2 and on expression of interleukin 2 receptor.

Authors:  R D Wang; Y Luo; Z H Feng; Z C Chen
Journal:  J Tongji Med Univ       Date:  1990

9.  Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinoma.

Authors:  M Nelson; D S Nelson; V K Kuchroo; P B Spradbrow; P A Jennings
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Splenocytes from tumor-bearing Corynebacterium parvum treated mice maintain interleukin-2 and -3 activity.

Authors:  A M Roberson; K D Elgert
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.